Lung Cancer News and Research

Latest Lung Cancer News and Research

New report provides overview of cancer risk among U.S. Hispanics/Latinos

The cancer burden in Puerto Rico, a U.S. territory with a 99% Hispanic population, is substantially different from that of Hispanics in the continental U.S., according to Cancer Statistics for Hispanics/Latinos, 2018.

4 Oct 2018

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, announces the availability of Brightplex, a novel high capacity IHC multiplex technology enabling multiple biomarkers to be analyzed on a single FFPE slide.

4 Oct 2018

Natural compound found in grapes may protect against cancer

Lung cancer is the deadliest form of cancer in the world, and 80% of death are related to smoking. In addition to tobacco control, effective chemoprevention strategies are therefore needed.

3 Oct 2018

Aggressive breast cancer hijacks normal protective physiological process to survive

A member of a protein family known for protecting our cells also protects cancer cells in aggressive, metastatic breast cancer, scientists report.

3 Oct 2018

Study highlights need for measures to improve annual lung cancer screening adherence

A study from the Thoracic Oncology Research Group, Division of Pulmonary Critical Care, Medical University of South Carolina aimed to examine the adherence to annual low-dose computed tomography screening after baselines LDCT within the Veteran Health Administration Lung Cancer Screening Demonstration Project.

1 Oct 2018

Researchers design new combination therapy for reducing NSCLC cell growth

Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.

29 Sep 2018

Cancer risk due to lifestyle and environmental factors can be prevented

Almost four in every 10 new cases of cancer in Germany are attributable to lifestyle and environmental factors. These include primarily smoking, low physical activity, overweight, and infections.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

Exploring parallels between biological and computing world

RNA-based algorithms can advance cellular computing and enable new biological solutions for healthcare and industrial biotechnology.

26 Sep 2018

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.

26 Sep 2018

Hybrid operating room enables faster diagnosis, treatment of patients with lung cancer

Representing a paradigm shift in thoracic surgery, the hybrid operating room combines three techniques into a single appointment eliminating multiple clinical visits for improved patient experience and outcomes.

25 Sep 2018

Study: Women with non-small cell lung cancers live longer than their male counterparts

Women diagnosed with non-small cell lung cancers live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, MD, the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine, at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto, Ontario, Canada.

25 Sep 2018

Lancaster professor aims to understand how genes affect smoking cessation

The Canadian Institute of Health Research has awarded $929,475 to Professor Jo Knight of Lancaster Medical School, Lancaster Data Science Institute and the Department of Psychiatry at the University of Toronto.

25 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Lung cancer patients treated with invasive surgery more likely to become chronic opioid users

Patients treated with more-invasive surgical techniques for a type of early-stage lung cancer are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery might be a contributing factor to the opioid addiction crisis, according to a study published in JAMA Oncology in September.

24 Sep 2018

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

24 Sep 2018

SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship

The Society of Nuclear Medicine and Molecular Imaging is pleased to announce the recipients of the 2018-2020 SNMMI Wagner-Torizuka Fellowship.

24 Sep 2018

Lung Cancer News and Research

Latest Lung Cancer News and Research

New report provides overview of cancer risk among U.S. Hispanics/Latinos

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

Natural compound found in grapes may protect against cancer

Aggressive breast cancer hijacks normal protective physiological process to survive

Study highlights need for measures to improve annual lung cancer screening adherence

Researchers design new combination therapy for reducing NSCLC cell growth

Cancer risk due to lifestyle and environmental factors can be prevented

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Non-small cell lung cancer patients survive longer when treated with durvalumab

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Exploring parallels between biological and computing world

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Hybrid operating room enables faster diagnosis, treatment of patients with lung cancer

Study: Women with non-small cell lung cancers live longer than their male counterparts

Lancaster professor aims to understand how genes affect smoking cessation

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Lung cancer patients treated with invasive surgery more likely to become chronic opioid users

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

SNMMI announces recipients of 2018-2020 Wagner-Torizuka Fellowship

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in